The Book · public · updated weekly
Our own book. Read in the open, every week.
A machine-run portfolio marked against the S&P 500, and a desk that has to explain every position, every week, wins and losses alike.
Tracked live in the open, losses included. Past performance does not guarantee future results.
TRACK RECORD · WEEKLY · 2026-10-28
EDIT and PANW drive a +18.84% excess week; cumulative lead hits a new peak
The book gained 18.67% this week while the S&P 500 slipped 0.17%, a spread of +18.84%. Since inception in December 2023, the book is up 343.8% against the S&P's 68.6%, a cumulative lead of +275.2% that just reached its highest point on record.
Book this week
+18.67%
S&P 500
-0.17%
Excess
+18.84%
What drove it
WHY IT PERFORMS
Two positions did most of the work: Editas jumped 17.5%, adding 1.75% to the book, and Palo Alto Networks surged 13.6%, adding another 1.36%. The remaining holdings contributed modest positives or near-flat moves, so this week was concentrated rather than broad. The twelve-week excess trend, up 65.75%, confirms the structural picture remains intact beyond any single week.
THE EXPOSURE (sector tilts, deliberate absences, specialist depth vs the universe and theme overlaps) is in the full report.
THE POSITION ROOM · ONLY WHERE SOMETHING HAPPENED
EDIT
Editas Medicine, the clinical-stage gene-editing company developing EDIT-401 as a one-time therapy to reduce LDL cholesterol, gained 17.5% after regulators approved its first-in-human trial. The news confirmed what the positioning evidence had already registered at entry.
3 more position reads this week
Create your accountFull performance history on the record page. Tracked live in the open. The record, not a forecast.